Pharma Focus Europe

Avicanna and Medipharm Labs Enhance Collaborative Manufacturing Agreement for Avicanna's Proprietary SEDDS Technology Capsules in Canadian and Global Markets

Tuesday, June 27, 2023

Avicanna Inc., a biopharmaceutical company focused on plant-derived cannabinoid-based products, has announced an extension of its strategic manufacturing agreement with Medipharm Labs Inc. The agreement aims to commercialize Avicanna's proprietary cannabinoid-based Self-Emulsifying Drug Delivery Systems (SEDDS) technology capsules in both the Canadian and international markets.

According to Aras Azadian, CEO of Avicanna, the company is pleased to partner with Medipharm, as they have demonstrated the necessary capabilities and alignment to manufacture and deliver these products across various markets and channels. Azadian also expressed excitement about the potential of Avicanna's single-dose formulations in the medical and pharmaceutical cannabinoid sectors.

Under the expanded agreement, Avicanna plans to commercialize its SEDDS technology capsules, branded as RHO Phyto, through domestic medical channels such as the Avicanna's MyMedi.ca online platform and MediPharm's Canna farms platform. MediPharm, on the other hand, intends to market the capsules in adult-use wellness channels under its own MediPharm Labs brand.

The agreement also includes provisions for manufacturing the capsules according to Good Manufacturing Practices (GMP) to meet domestic and international pharmaceutical standards. MediPharm will manufacture the capsules, and both Avicanna and MediPharm will explore opportunities for international distribution through their internal infrastructure and external contracted parties.

Avicanna's SEDDS capsules address the challenges associated with the poor absorption and variable onset of current cannabinoid formulations due to their low water solubility and lipophilic nature. The company's proprietary SEDDS technology has demonstrated shelf-life stability, with over 90% of cannabinoids remaining after six months in accelerated conditions. Dissolution profiles of CBD and THC in biorelevant media, simulating human intestinal fluid, showed over 90% dispersion within one hour, indicating effective oral administration. Avicanna plans to further develop specific formulations through pre-clinical and clinical development.

In summary, Avicanna and Medipharm have extended their strategic manufacturing agreement to commercialize Avicanna's SEDDS technology capsules in Canada and internationally. The collaboration aims to cater to the medical, pharmaceutical, and wellness segments, providing innovative solutions for cannabinoid delivery.

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva